Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group

作者：Thomas Seufferlein, Waldemar Uhl, Marko Kornmann, Hana Algül, Helmut Friess, Alexander König, Michael Ghadimi, Eike Gallmeier, Detlef K. Bartsch, Manfred P. Lutz, Ralf Metzger, Kai Wille, B. Gerdes, Carl Christoph Schimanski, F Graupe, Volker Kunzmann, Ingo Klein, Michael Geißler, Ludger Staib, D. Waldschmidt, Christiane J. Bruns, Uwe A. Wittel, Stefan Fichtner‐Feigl, S Daum, Axel Hinke, L. Blomé, Andrea Tannapfel, Alexander Kleger, Adam Berger, Angelika Kestler, J.S. Schuhbaur, Lukas Perkhofer, Margaret A. Tempero, Anke Reinacher‐Schick, Thomas J. Ettrich · 发表于：Annals of Oncology · 年份：2022 · DOI：10.1016/j.annonc.2022.09.161 · 被引用次数：165 · 研究领域：Pancreatic and Hepatic Oncology Research、Cancer, Stress, Anesthesia, and Immune Response、Cholangiocarcinoma and Gallbladder Cancer Studies